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Introduction: Rheumatoid arthritis (RA) is associated with a high cardiovascular disease (CVD) risk, whereas arterial
hypertension is a major modifiable CVD risk factor with still unclear prevalence in RA disease. We conducted a
comprehensive study on hypertension characteristics evaluating for the first time out-of-office blood pressure (BP)
in a typical contemporary RA cohort.
Methods: Assessment of office and out-of-office BP (when office systolic/diastolic BP was >129/79) and vascular
studies including evaluation of aortic stiffness, carotid hypertrophy/plaques and ankle-brachial index, were
performed in 214 consecutive, consenting RA patients free of CVD (aged 58.4 ± 12.3 years, 82% women). As
comparators regarding office hypertension measurements, data from 214 subjects (1:1 matched for age and gender
with the RA patients) derived from a cohort designed to assess the prevalence of hypertension in the general
population were used.
Results: The prevalence of declared known hypertension in the RA population was 44%. Of the remaining RA
patients, 2 in every 5 individuals had abnormal office BP (systolic/diastolic >139/89 mmHg), contributing to almost
double the prevalence of declared/office hypertension compared to the general matched population (67% vs. 34%).
Out-of-office (home or ambulatory 24 hour) BP measurements revealed that: (i) a 54% prevalence of actual
hypertension in RA, in other words almost 10% of the patients were unaware of having hypertension and (ii) 29%
of the RA patients with known hypertension were not well controlled. Actual hypertension was positively
associated with age and body mass index, and inversely with the use of biologic drugs. Overall, almost 1 out of 5
presented the ‘white coat’ phenomenon. An intermediately compromised vascular phenotype was evident in this
“white coat” subgroup (lying between patients with sustained normotension and sustained hypertension) in terms
of aortic stiffness, carotid hypertrophy and ankle-brachial index, even after adjustment for confounders.
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Conclusion: Beyond any doubt on the basis of out-of-office evaluation, arterial hypertension in RA has a high
prevalence, low awareness and poor control, as well as substantial and vascular damage-associated “white coat”
phenomenon. Thus, correct diagnosis and effective treatment of hypertension is of key importance in RA for CVD
risk reduction.Introduction
Compared to the general population, patients with rheu-
matoid arthritis (RA) have almost twice the risk of devel-
oping cardiovascular disease (CVD) [1] and their risk for
myocardial infarction corresponds to that of non-RA
patients who are 10 years older [2]. CVD mortality
accounts for almost half of all-cause mortality in RA
[3,4]. This is thought to be mediated by accelerated ath-
erosclerosis [5,6] and subclinical vasculitis [7,8]. The
increased burden of established CVD risk factors in RA
patients [9] explains only partly the excess CVD mortal-
ity [10], suggesting that systemic inflammation partici-
pates in the development of CVD.
Arterial hypertension is a major modifiable CVD risk fac-
tor worldwide [11]. Previous studies suggest that the preva-
lence of hypertension is increased in RA [12,13], possibly
related to clinical status [14] and the related physical in-
activity [15] as well as to genetic factors [16,17]. As recently
reviewed, however, the evidence is still conflicting [18]. This
is in part due to the fact that the existing data are based on
single-visit office blood pressure (BP) readings, whereas
data based on out-of-office BP evaluation (which provides
the gold-standard assessment of BP-associated CVD risk
[19]) are lacking. As a result, data on white coat hyperten-
sion (WCH) and masked hypertension (MH) phenomena,
two BP phenotypes associated with potentially intermediate
CVD risk [19], are also lacking in RA patients.
Elevated BP in RA may derive from increased oxidative
stress and systemic inflammation, impaired endothelial
function, vasoconstriction and increased total peripheral
resistance, as well as arterial stiffening [5,9,12,13]. RA-
related drugs, such as corticosteroids and nonsteroidal
anti-inflammatory drugs, and particular genetic polymor-
phisms, together with environmental factors, may also
precipitate BP elevation in RA [12,13,16,17]. In contrast,
anti–tumor necrosis factor and anti–interleukin 6 bio-
logics appear to have beneficial effects on endothelial
function and arterial stiffness [20,21] and thus may reduce
BP independently of Disease Activity Score [14].
In a contemporary cohort of consecutive RA patients
free of established CVD, we evaluated BP and assessed
vascular organ damage. Our principal hypotheses were (1)
that the prevalence of hypertension in RA is higher than
that in the general population and (2) that specific BP
diagnostic phenotypes, such as WCH and MH phenom-
ena, have different clinical significance in terms of vasculardamage in RA patients. The following were our specific
aims: (1) to compare the prevalence of abnormal office BP
measurements to those observed in a 1:1 age- and gender-
matched general population group free of CVD, (2) to as-
sess the actual prevalence of hypertension in RA by apply-
ing, for the first time, out-of-office BP measurements to
identify the awareness and effectiveness of BP control as
well as the prevalence of resistant hypertension, (3) to
identify factors associated with the presence of hyperten-
sion in RA and (4) to identify specific BP diagnostic phe-
notypes, such as WCH and MH phenomena, and their
association with the extent of vascular damage.
Methods
The present study was approved by the Ethical/Scientific
Committee of the “Laikon” Hospital, and all participants
provided their informed consent to participate according
to the Declaration of Helsinki.
Rheumatoid arthritis patients
From September 2010 until September 2012, 242
consenting, consecutive patients (mean age 59.2 ± 12.3
years, 195 women (81%)) attending the outpatient
Rheumatology Clinic and meeting the American College
of Rheumatology classification criteria [22] were examined
at the Cardiovascular Research Laboratory for global CVD
risk stratification. Ninety-five percent of them were inhabi-
tants of the Attica province of Greece (which includes 78%
urban and 22% rural areas – mainly the city of Athens and
its suburbs). All patients underwent a medical interview
and examination so that we could record all the known
classical CVD risk factors and drug treatments as well as
the presence of CVD. All biochemical data were retrieved
from the patient’s records at the outpatient Rheumatology
Clinic of the department. The estimated creatinine clear-
ance (eCCL) was assessed by using the Cockcroft-Gault
formula. Two hundred fourteen RA patients were included
in the present analysis (mean age 58.4 ± 12.3 years, 176
women (82%)) after excluding 18 patients with established
CVD, 2 with estimated creatinine clearance less than
30 ml/min (due to the possibility of secondary hyperten-
sion) and 8 patients without available office BP recordings.
Control group
RA patients were matched 1:1 by age and sex with 214
individuals randomly derived from the ATTICA study
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population-based health and nutrition survey that was
conducted from May 2001 to December 2002 in the
province of Attica, Greece. The original sample included
3,042 participants, and the data selection was performed
among 2,285 (1,128 men) who were free of CVD or in-
flammatory disease.
Protocols for arterial blood pressure and hypertension
assessment
BP in RA patients was measured in the morning (8:30 AM
to 12:30 PM) during the vascular tests after at least ten
minutes of rest in the supine position under controlled
room temperature (22°C to 25°C). Triple BP recording
was performed (with one-minute intervals between
readings) using the right arm and a previously validated
automated oscillometric device (WatchBP Office;
Microlife AG, Widnau, Switzerland) [24]. The averageN=242
consecutive RA patients w
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Figure 1 Flow of the blood pressure assessment methods used in the
rheumatoid arthritis.of the three BP readings was calculated and used in the
subsequent analysis.
All participants with office systolic (S)BP/diastolic (D)BP
129/79 mmHg or lower were considered to have optimal
office BP and thus to have low probability of exhibiting the
MH phenomenon, since this is particularly observed in in-
dividuals with high normal office BP [25]. All others were
advised to perform out-of-office BP measurements (either
home BP monitoring (HBPM) or 24-hour ambulatory BP
monitoring (ABPM) according to their own preference).
These two methodologies are equally recommended by
the European Hypertension Society (ESH) 2007 guidelines
[19] for the detection of the WCH and MH phenomena.
HBPM was performed with a previously validated auto-
mated oscillometric device (WatchBP Home, Microlife
AG) [26] according to the ESH suggested protocol (seven-
day BP recordings) [27]. All patients underwent a brief tu-
torial about how to use the BP device correctly and how toho 
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rheumatoid arthritis population. BP, blood pressure; RA,
Table 1 Definitions of hypertension phenotypes
according to the European Society of Hypertension
recommendationsa
Characteristics Definitions
Optimal office BP Systolic BP ≤129 and Diastolic BP ≤79
Abnormal/uncontrolled
office BP
Systolic BP >139 or Diastolic BP >89
Abnormal/uncontrolled
home BP
Systolic BP >134 or Diastolic BP >84
Abnormal/uncontrolled
24-hour BP
Systolic BP >129 or Diastolic BP >79












Abnormal/uncontrolled office BP in the
presence of normal out-of-office BP
Sustained normal BP Normal office BP in the presence of normal
out-of-office BP
Sustained elevated BP Abnormal/uncontrolled office BP in the
presence of abnormal/uncontrolled out-of-
office BP
Known hypertension Medical interview defined status as presence
of BP-lowering drug treatment or under
lifestyle modification for previously diagnosed
hypertension
aBP: blood pressure (mmHg). Definitions are based on the European Society of
Hypertension Guidelines [19,27].
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The HBPM data were downloaded and analyzed using spe-
cifically designed software (TRITON software package;
Proton Labs, Athens, Greece) according to the built-in
ESH recommendations [27]. ABPM measurements were
performed according to the ESH 2007 guidelines [19]
using a previously validated automated oscillometric de-
vice (90207 ambulatory blood pressure monitor; Spacelabs
Healthcare, Snoqualmie, WA, USA) [28]. All patients were
advised to perform their regular activities during ABPM.
Overall, 93 of the 214 RA patients had optimal office
BP readings. The data provided in the results were cal-
culated with the assumption that RA patients with opti-
mal office BP would have normal out-of-office BP. From
among the remaining patients, 24 underwent 24-hour
ABPM and 58 underwent HBPM, whereas 39 RA pa-
tients did not consent to undergo out-of-office BP as-
sessment. Figure 1 summarizes the protocol’s flow on
the basis of BP assessment methodology. These 39 pa-
tients had characteristics similar to those of the overall
cohort (mean age, 62.1 ± 12.1 years; 82% women; mean
body mass index, 28.9 ± 6.2 kg/m2; abnormal office BP,
36 patients; high normal BP, 3 patients; and hyperten-
sives under antihypertensive drug treatment, 14) and
were excluded from the analysis regarding the pre-
valance of WCH and MH phenomena, as well as regard-
ing the prevalence of out-of-office hypertension (unless
already under drug treatment; n = 14). This fact may
not have led to important underestimation of the MH
phenomenon, because only three of the thirty-nine pa-
tients had high normal office BP (Figure 1).
All the definitions of the hypertension phenotypes
which have been applied were based on the ESH guide-
lines and are summarized in Table 1 [19,27].
With regard to the control subjects, BP was measured at
the end of the physical examination in participants’ work-
places or at their homes while they were in the sitting pos-
ition and had been at rest for at least 30 minutes [29]. BP
recordings were performed by a cardiologist three times at
the right arm, which was relaxed at a 45° angle from the
trunk and well-supported by a table (ELKA aneroid sphyg-
momanometer; Von Schlieben Co, Munich, Germany).
The SBP level was determined by the first perception of
sound (of tapping quality). The DBP was determined by
phase V, when the repetitive sounds become fully muffled
(that is, disappear). The same criteria used for RA patients
were applied for BP classification.
Vascular studies
Vascular organ damage assessment included the investi-
gation of aortic stiffness (carotid to femoral pulse wave
velocity (PWV)), common carotid hypertrophy (cross-
sectional area (CSA)) and carotid atheromatosis (carotid
plaques) as previously described in detail [5]. TheAnkle-Brachial Index (ABI) was assessed using a vali-
dated oscillometric automated device (WatchBP Office
ABI; Microlife AG) [30]. All the vascular measurements
were performed by the same experienced and dedicated
technician (GD Konstantonis) after BP recording. All
participants were advised to abstain from any vasoactive
drug or substance (including BP-lowering drugs) on the
morning of the vascular examination.
Statistical analysis
Variables were tested for normality by the Kolmogorov-
Smirnov test. Paired t-test, χ2 and Wilcoxon test were
applied for comparison of the 1:1 matched RA and con-
trol populations as appropriate. Binary logistic regression
analysis was applied to find the independent predictors
of hypertension and BP control. The classical determi-
nants, namely, age, body mass index and sex traits, were
constantly used in all models to further identify RA-
related and non-RA-related parameters which were as-
sociated with the dependent variables. Regression ana-
lysis, analysis of variance and analysis of covariance (to
adjust for potential confounders) were applied to detect
differences between diagnostic BP phenotypes. Signifi-
cance was defined as P < 0.05 throughout. Statistical
analysis was performed using SPSS version 19.0 software
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as means ± SD or percentages, and non–normally dis-
tributed continuous variables are presented as median
values (50th quartile) with interquartile ranges (25th to
75th quartiles) as appropriate.
Results
Prevalence, awareness and control of hypertension in
rheumatoid arthritis
The prevalence of known hypertension was 44% in the RA
cohort. Of the remaining RA patients, almost two of every
five had abnormal office BP measurements, reaching an
overall rate of 67% (males: 74%, females: 66%) of office
BP-defined hypertension (Figure 2). This ratio was almost
double that found in the 1:1 age- and gender-matched
control group (34%; males: 37%, females: 33%). RA pa-
tients had no statistically significant differences in hyper-
cholesterolemia, diabetes mellitus, current smoking and
body mass index compared to the control group from the
ATTICA study (Table 2). Interestingly, although matched
for age and gender, women with RA had a higher preva-
lence of menopause than women in the control group. RA
patients had higher C-reactive protein levels than the con-
trols (Table 2).
Out-of-office BP assessment (either seven-day HBPM
or twenty-four-hour ABPM) revealed that the actual0
Actual hypertension (on the basis of
home 7-days or 24 hour ambulatory
blood pressure monitoring) in the RA
cohort
Hypertension in the age- & gender-
mathced general population (ATTICA
study)
Office hypertension in the RA cohort
Known hypertension in the  general
population (ATTICA study)*
Known hypertension in the RA cohort
Figure 2 Prevalence of blood pressure levels under the studied cond
actual blood pressure (BP) on the basis of out-of-office BP assessment, eith
monitoring, in the overall rheumatoid arthritis cohort as well as in the genprevalence of hypertension in RA was 54% (males: 55%;
females: 54%). As a consequence, approximately an add-
itional 10% of the overall population were unaware that
they had hypertension (Figure 2). Moreover, 29% of the
RA patients with known hypertension had uncontrolled
out-of-office BP. Overall, about one of every two RA pa-
tients (52%) with known hypertension had abnormal
out-of-office BP despite antihypertensive treatment.
Among the hypertensive RA patients, the prevalence of
resistant hypertension (defined as uncontrolled BP in the
presence of at least three antihypertensive drugs, including
a diuretic) was 9% on the basis of office BP measurements
or 5% on the basis of out-of-office BP readings.
Factors associated with hypertension and uncontrolled
blood pressure in rheumatoid arthritis
All the RA-related and nonrelated parameters were
assessed on the basis of logistic regression analysis, with
data presented as multivariate adjusted odds ratios
(aOR) and 95% confidence intervals (CI). Abnormal of-
fice BP measurements were positively associated with
age (aOR = 1.08; 95% CI = 1.04 to 1.2), body mass index
(aOR = 1.11; 95% CI = 1.04 to 1.21), presence of meno-
pause (aOR = 4.8; 95% CI = 1.6 to 14.3) and male gender
(aOR = 3.3; 95% CI = 1.07 to 10.2). Abnormal office BP






itions. Bar graph shows the prevalence in percent of known, office and
er seven-day home BP monitoring or twenty-four-hour ambulatory BP
eral population of the ATTICA study.
Table 2 Demographics of the 214 patients with





Hypercholesterolemia (%) 42 28 0.176
Diabetes mellitus (%) 6 13 0.462
Current smokers (%) 30 42 0.089
Women in menopause (%)b 77 61 <0.001
Body mass index (kg/m2) 27.1 ± 5.4 25.6 ± 6.4 0.430
Total cholesterol (mg/dl) 205.6 ± 36.9 199.8 ± 40.6 0.450
Glucose (mg/dl) 93.0 ± 19.0 94.7 ± 31.10 0.419
Creatinine (mg/dl) 0.8 ± 0.2 n/a
eCCL (ml/min) 96.0 ± 33.4 -
C-reactive protein (mg/dl) 4.5 (2.2 to
11.4)
1.0 (0 to 3) <0.001
Use of antihypertensive drugs (%) 44 34c –
RA-related drugs (%)
Corticosteroid (%) 70 –
Methotrexate (%) 58 –
Leflunomide (%) 17 –




Biologic drugs (%) 35 –
Hydroxychloroquine (%) 5 –
aeCCL, estimated creatinine clearance using the Cockcroft-Gault formula; RA,
rheumatoid arthritis. The RA patients had a mean age of 58.4 ± 12.3 years, and
82% were females. The study patients were age- and gender-matched 1:1 with
a control group from the ATTICA study. Data are presented as means ± SD or
medians (interquartile range) and analyzed by paired t-test, χ2 test and
Wilcoxon test as appropriate. bData were available for 170 of 176 female RA
subjects and 132 of 176 controls. cData are derived from a previously
published paper [35].
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cise was marginally excluded from the model. The pres-
ence of actual (out-of-office) hypertension was positively
associated only with age (aOR = 1.09; 95% CI = 1.06 to
1.36) and body mass index (aOR = 1.15; 95% CI = 1.06
to 1.25) and was inversely associated with the use of bio-
logic drugs (aOR = 0.46; 95% CI = 0.21 to 0.99). Among
the hypertensive RA patients, the use of leflunomide was
the only RA-related parameter that was associated with
uncontrolled out-of-office BP (aOR = 3.63; 95% CI =
1.04 to 12.65), even after adjustment for age, body mass
index and gender.
Blood pressure diagnostic phenotypes in rheumatoid
arthritis and vascular damage
Less than 1% of the RA population exhibited the MH
phenomenon. On the contrary, of all RA patients, al-
most one (21%) of every five exhibited the WCH
phenomenon; that is, 29% of those treated forhypertension (Figure 3a) and 19% of those not treated
for hypertension (Figure 3b) had WCH. Interestingly,
these patients, regardless of the presence or not of anti-
hypertensive treatment (data not shown), presented an
intermediately compromised vascular phenotype as
assessed by well-established biomarkers of arterial dam-
age (Table 3). As shown in Table 3, WCH was associated
with compromised aortic stiffness (PWV), common ca-
rotid hypertrophy (CSA), carotid plaques and ABI, all
biomarkers which are related to CVD mortality in both
hypertension and RA, at levels between sustained
normotension and sustained hypertension, although out-
of-office BP levels were comparable between the WCH
and sustained normotension groups. Because significant
differences in age, body mass index and smoking were
found between the three groups (Table 2), we performed
further adjustment for potential confounders (including
age, gender, body mass index, smoking and mean BP)
and found that the differences regarding PWV, right
CSA and right ABI persisted between the three groups
(Table 2).
Discussion
This is the first detailed study of the prevalence and
characteristics of hypertension in RA patients without
established CVD. It included age- and sex-matched non-
CVD controls from the same geographical area and race;
it utilized assessment of both office and out-of-office BP,
thus enabling estimation of the actual prevalence of
hypertension in RA, as well as of the WCH and MH
phenomena, which are important in terms of awareness
and inadequate therapy; and it incorporated assessment
of vascular damage, allowing the exploration of its asso-
ciations with specific hypertension phenotypes.
The novel important findings of our present study,
based on out-of-office BP, are as follows. (1) The preva-
lence of hypertension in RA was clearly elevated (54%)
compared to that in the general population (34%), and it
would have been even higher if out-of-office BP assess-
ment were available in the ATTICA study. (2) About
10% of the overall RA cohort (or one of every four RA
patients with confirmed hypertension) were not aware
that they had hypertension. (3) One of every two pa-
tients in the overall RA population (or one in every three
RA patients with confirmed hypertension) had uncon-
trolled BP. (4) The prevalence of the MH phenomenon
was negligible. (5) The WCH phenomenon was observed
in almost one of every five RA patients overall, which
should be regarded as an intermediate to high CVD risk
BP phenotype in patients with RA because of the pres-
ence of accelerated atherosclerosis, thus raising ques-
tions about the optimal BP treatment strategy in this
population. (6) We verified that particular RA treatment




















Figure 3 Prevalence of white coat and masked hypertension phenomena in the rheumatoid arthritis cohort. (a) Patients treated for
hypertension. (b) Patients not treated for hypertension.
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fere with BP control in addition to classical factors such
as age and body mass index.
The observed high prevalence of hypertension (67%)
on the basis of office BP is in accordance with previously
reported data from studies in which similar office BP
measurements were taken (70% in a population with a
mean age 63 years [12] and 57% in a population with a
mean age of 59 years [13]). Most importantly, even the
actual prevalence of hypertension in RA on the basis of
out-of-office BP assessment was 1.6 times that in the AT-
TICA study. The data derived from the ATTICA study
were based on single-visit BP recordings (at the partici-
pants’ workplaces or homes) and are in general agreement
with those reported in other studies in the Greek popula-
tion, which were based on office BP readings [31-35]. It is
thus expected that the prevalence of hypertension in the
ATTICA study would be lower if based on out-of-office
BP methods (either HBPM or ABPM).
A major aim of the present study was to compare the
prevalence of hypertension in a typical contemporary co-
hort of RA patients to the prevalence of hypertension in
the general population. Therefore, among all the relevantpreviously published Greek studies, we decided to use
the most contemporary one in the general population
and the one which was carried out in exactly the same
region as the RA cohort (Attica, Athens). The ATTICA
study was performed almost 10 years before the time the
data from the present RA cohort were gathered and thus
may not depict the updated prevalence of hypertension
in the current general population, but the results are in
line with all other epidemiological studies published be-
fore or since [31-35]. The fact that the precise method
of BP measurement differed between the RA and non-
RA cohorts may have influenced the results. However,
we believe that the magnitude of the difference (twofold)
observed in the prevalence of office hypertension be-
tween the RA and general populations in this study is
extremely unlikely to be due to these limitations. As
such, we suggest that the evidence for a higher preva-
lence of hypertension in RA compared to the general
population can be considered conclusive.
The reason for the increased prevalence of hypertension
in RA is not clear. In the present study, and in agreement
with two previous studies [12,13], a direct association be-
tween the prevalence of hypertension and inflammation
Table 3 Blood pressure phenotypic phenomena and











115.1 ± 9.2 142.9 ± 11.1 151.8 ± 16.6
Office DBP
(mmHg)
70.9 ± 5.8 82.2 ± 7.0 86.2 ± 9.5
Out-of-office
SBP (mmHg)
123.7 ± 9.5 121.6 ± 7.3 141.2 ± 8.3
Out-of-office
DBP (mmHg)





13.1 ± 3.0 14.5 ± 3.7 15.1 ± 3.2 0.002/0.251b
R CCA CSA
(mm2)
12.5 ± 2.8 14.0 ± 3.8 15.2 ± 2.7 <0.001/0.027b
Presence of
plaque (%)
49 59 72.5 0.044/0.354b
PWV (m/s) 7.8 ± 1.7 8.9 ± 2.7 9.8 ± 2.7 <0.001/<0.001c
L ABI (%) 1.23 ± 0.1 1.19 ± 0.9 1.21 ± 1.0 0.233
R ABI (%) 1.22 ± 0.1 1.14 ± 0.1 1.18 ± 0.1 0.002/<0.001c
CV risk factors
Age, years 55.4 ± 12.7 59.7 ± 11.1 60.9 ± 10.8 0.026
Females (%) 86 84 70 0.067




Current 38 16 25
Ex-smokers 14 19 30
Dyslipidemia
(%)
18 24 30 0.328
BMI (kg/m2) 25.5 ± 4.8 28.1 ± 4.3 28.1 ± 5.7 0.003
aABI, Ankle-Brachial Index; BMI, body mass index; BP, blood pressure; CCA,
common carotid artery; CV, cardiovascular; CSA, cross-sectional surface area;
DBP, diastolic blood pressure, DM, diabetes mellitus; L, left; R, right; SBP,
systolic blood pressure; SH, sustained hypertension; SN, sustained
normotension; WCH, white coat hypertension. bAdjusted for age, gender, BMI
and smoking. cAdjusted for age, gender, BMI and smoking and for mean office
BP. Data were analyzed by regression analysis, analysis of variance or analysis
of covariance as appropriate. Data in the SN group are presented only for
those patients who had high normal office BP and as a consequence were
advised to measure out-of-office BP.
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However, we cannot exclude that systemic inflammation
plays a role in the development of hypertension in RA,
because (1) RA inflammation fluctuates, and this cross-
sectional marker may not capture the long-term cumula-
tive inflammatory burden, and (2) the studied population
was well-controlled with conventional and biologic drugs,
which affect C-reactive protein, endothelial function, ar-
terial stiffness and BP levels [14,20,21]. Moreover, in the
present study, the prevalence of menopause was increasedby 15% in RA compared with the matched general female
population and was independently associated with office
hypertension. Given the fact that early menopause has
been associated with increased prevalence of hypertension
[36], as well as with the incidence of RA [37], these find-
ings may represent a pathogenic link between hyperten-
sion and RA. However, biologic drugs exert a beneficial
effect on endothelial function and arterial stiffness [20,21]
and thus may prevent the incidence of hypertension [14].
The need to improve the awareness of hypertension
among hypertensive RA patients is highlighted by the
present study, in which the actual percentage of un-
awareness was 23% based on out-of-office BP measure-
ments. Data based on out-of-office BP measurement are
lacking in large general population groups. For purposes
of comparison, we report herein the corresponding data
from the present RA cohort on the basis of office BP
measurements. Using these measurements, 46% of RA
patients with hypertension were not aware that they had
it, whereas the published data from the ATTICA study
in a similar age group (55 to 65 years old) were about
40% [35]. In a previous study, about 35% of a RA cohort
in the same age group (55 to 65 years old) who were un-
aware of their hypertension [12].
Moreover, the present data emphasize the need to im-
prove the effectiveness of BP treatment in RA because
29% (on the basis of out-of-office BP) or 35% (on the basis
of office BP) of those who were aware of having hyperten-
sion had uncontrolled BP. The published data from the
ATTICA study in a similar age group (55 to 65 years old)
were about 34% [35]. In a previous RA cohort in the same
age group (55 to 65 years old), this figure was about 55%
[12]. Physicians taking care of RA patients should
optimize treatment control by taking into consideration
the fact that leflunomide, as shown in the present study
and as previously described [38], restricts effective BP con-
trol. Although the underlying mechanism is not clear, it is
suggested that it might be mediated by the activation of
the sympathetic nervous system [38]. Previous studies
[12,13] have not provided consistent results regarding
other RA-related drugs (for example, corticosteroids,
nonsteroidal anti-inflammatory drugs). Similarly, in the
present study, we did not identify the well-described effect
of corticosteroids [39] and nonsteroidal anti-inflammatory
drugs on BP. This is most probably related to treatment
preferences that prevail in each cohort. In the present
study, only 5% of patients were being treated with nonste-
roidal anti-inflammatory drugs and only low-dose cortico-
steroids (less than 5 to 7 mg/day) were used. The latter
may have undetectable effects on BP level as previously
discussed [12]; however, their effects may be deleterious
for the arteries in the long run, and thus their use should
be carefully considered [40]. Notably, in the present study,
body mass index was associated with the presence of
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with poor BP control. Therefore, the described paradoxical
association of obesity with decreased CVD in RA patients
[9] seems to be mediated by other pathways that counter-
balance the effect of obesity on BP.
Data regarding the prevalence of resistant hyperten-
sion in RA are lacking so far. In this cohort, the preva-
lence was found to be relatively high (9% in RA vs. 5% in
the general population as published in the literature on
the basis of office BP readings) [41]. However, this issue
needs further thorough investigation because significant
differences exist regarding the prevalence of resistant
hypertension from population to population [41]. Fur-
ther research is also needed to elucidate whether poor
BP control in RA is due to the well-described worldwide
physician’s inertia [42,43] or whether RA-specific peculi-
arities, such as treatment modalities, increase the preva-
lence of resistant hypertension and/or the presence of
increased aortic stiffness [5,44], also contribute.
The optimal BP diagnostic method and the goals of
treatment are unresolved issues in hypertension research
[19]. The results of our present study suggest that there
are peculiarities in the RA population because of the
negligible prevalence of MH (less than 1% vs. the antici-
pated 10% to 15% in the general population [19]),
whereas the prevalence of the WCH phenomenon was
relatively high (21% vs. the anticipated 15% in the gen-
eral population [19]). High prevalence of the WCH
phenomenon has also been described in diabetes
mellitus type 2 [45], which shares common characteris-
tics with RA [5], including increased arterial stiffness,
which may partly contribute to the WCH phenomenon.
The current hypertension guidelines advise clinicians
not to treat individuals who exhibit the WCH pheno-
menon unless there is evidence of target organ damage
[19]. In the present cohort, RA patients with the WCH
phenomenon (treated or not treated for hypertension)
presented with substantial vascular damage. The preva-
lence of carotid plaques was 60%, and we observed an
intermediate level of carotid hypertrophy, aortic stiffness
and reduced ABI compared to those RA patients with
sustained normotension and sustained hypertension.
These findings are in line with previous findings in non-
RA populations [19]. We suggest that, in similar cases,
the decision regarding office BP reduction in RA pa-
tients by either drug treatment titration (in those already
receiving antihypertensive drugs) or drug treatment ini-
tiation (in those currently untreated with drugs) should
be carefully weighed on the basis of patient age, the de-
gree of vascular damage, the presence of orthostatic
hypotension and, certainly, the out-of-office BP level.
This topic requires further research, given the fact that
target organ damage has quite a high prevalence in RA
and is closely related to hypertension [46].Conclusions
Physicians involved in the management of RA patients
should be alert to the high prevalence and low awareness
of hypertension on the basis of the present robust out-of-
office BP data. They should also take into consideration
the facts that specific RA treatment modalities have effects
on the management of arterial hypertension and that the
high prevalence of the WCH phenomenon is associated
with increased CVD risk; thus these patients require close
monitoring at the least. Hypertension is definitely a major
contributor to the well-established high CVD risk ob-
served in RA patients. As suggested by the recent recom-
mendations of the European League Against Rheumatism
[47], hypertension should be placed at the top of the
research agenda for the reduction of CVD risk in RA, and
future clinical trials should incorporate out-of-office BP
assessment in their design.
Abbreviations
ABI: Ankle-brachial index; ABPM: Ambulatory blood pressure monitoring;
ANCOVA: Analysis of covariance; ANOVA: Analysis of variance; BP: Blood
pressure; CSA: Cross-sectional area; CVD: Cardiovascular disease;
DBP: Diastolic blood pressure; ESH: European society of hypertension;
HBPM: Home blood pressure monitoring; MH: Masked hypertension;
PWV: Pulse wave velocity; RA: Rheumatoid arthritis; SBP: Systolic blood
pressure; SD: Standard deviation; WCH: White coat hypertension.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ADP made substantial contributions to the conception and design of the
study, as well as to the acquisition, analysis and interpretation of the data,
and was involved in drafting the manuscript and revising it critically. DBP
made substantial contributions to the conception and design of the study,
acquired data and was involved in revising the manuscript critically. EZ
acquired data and was involved in revising the manuscript. KA, AAA and GD
Konstantonis acquired data and were involved in critically revising the
manuscript. CP made substantial contributions to the conception and design
of the study and was involved in critically revising the manuscript. GD Kitas
made substantial contributions to the conception and design of the study
and to the interpretation of data and was involved in drafting the
manuscript and revising it critically. PPS made substantial contributions to
the conception and design of the study and to the interpretation of data
and was involved in drafting the manuscript and revising it critically. All
authors gave their approval of the final version of the manuscript for
publication.
Author details
1Rheumatology Unit and Cardiovascular Research Laboratory, First
Department of Propaedeutic and Internal Medicine, Laiko Hospital, Medical
School, National and Kapodistrian University of Athens, Athens, Greece.
2Department of Nutrition and Dietetics, Group of Biostatistics, Epidemiology
and Research Methods, Harokopio, University, Athens, Greece. 3First
Department of Cardiology, Ippokrateion Hospital, Medical School, National
and Kapodistrian University of Athens, Athens, Greece. 4The Dudley Group
NHS Foundation Trust, Dudley, and Arthritis Research Campaign
Epidemiology Unit, University of Manchester, Manchester, UK.
Received: 7 March 2013 Accepted: 20 September 2013
Published: 2 October 2013
References
1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D:
Risk of cardiovascular mortality in patients with rheumatoid arthritis: a
meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690–1697.
Protogerou et al. Arthritis Research & Therapy 2013, 15:R142 Page 10 of 11
http://arthritis-research.com/content/15/5/R1422. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB,
Torp-Pedersen C, Hansen PR: The risk of myocardial infarction in
rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort
study. Ann Rheum Dis 2011, 70:929–934.
3. Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ: Mortality and survival
in rheumatoid arthritis: a 25 year prospective study of 100 patients.
Ann Rheum Dis 1990, 49:363–369.
4. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, Dixey J,
Early Rheumatoid Arthritis Study (ERAS) Group: Mortality in rheumatoid
arthritis: increased in the early course of disease, in ischaemic heart disease
and in pulmonary fibrosis. Rheumatology (Oxford) 2007, 46:350–357.
5. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K,
Georgiopoulos G, Protogerou A, Panoulas VF, Sandoo A, Tentolouris N, Mavrikakis
M, Sfikakis PP: Atherosclerosis in rheumatoid arthritis versus diabetes: a
comparative study. Arterioscler Thromb Vasc Biol 2009, 29:1702–1708.
6. Giles JT, Post WS, Blumenthal RS, Polak J, Petri M, Gelber AC, Szklo M, Bathon JM:
Longitudinal predictors of progression of carotid atherosclerosis in
rheumatoid arthritis. Arthritis Rheum 2012, 63:3216–3225.
7. Toutouzas K, Sfikakis PP, Karanasos A, Aggeli C, Felekos I, Kitas G, Zampeli E,
Protogerou AD, Stefanadis C: Myocardial ischaemia without obstructive
coronary artery disease in rheumatoid arthritis: hypothesis-generating
insights from a cross-sectional study. Rheumatology (Oxford) 2013, 52:76–80.
8. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, Joshi FR, Ostör AJ, Hall FC, Rudd JH,
Wilkinson IB: Anti-tumor necrosis factor-α therapy reduces aortic
inflammation and stiffness in patients with rheumatoid arthritis.
Circulation 2012, 126:2473–2480.
9. Kitas GD, Gabriel SE: Cardiovascular disease in rheumatoid arthritis: state
of the art and future perspectives. Ann Rheum Dis 2011, 70:8–14.
10. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A: High incidence
of cardiovascular events in a rheumatoid arthritis cohort not explained by
traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737–2745.
11. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M,
Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators: Effect
of potentially modifiable risk factors associated with myocardial
infarction in 52 countries (the INTERHEART Study): case–control study.
Lancet 2004, 364:937–952.
12. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P,
Kita MD, Tselios AL, Metsios GS, Elisaf MS, Kitas GD: Prevalence and
associations of hypertension and its control in patients with rheumatoid
arthritis. Rheumatology (Oxford) 2007, 46:1477–1482.
13. Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS, Gelber AC,
Ouyang P, Jenny NS, Bathon JM: Prevalence of traditional modifiable
cardiovascular risk factors in patients with rheumatoid arthritis:
comparison with control subjects from the multi-ethnic study of
atherosclerosis. Semin Arthritis Rheum 2012, 41:535–544.
14. Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP,
Hulsmans HM, van Krugten MV, Speyer I, de Vries-Bouwstra JK, Kerstens PJ,
Huizinga TW, Dijkmans BA, Allaart CF: Blood pressure changes in patients
with recent-onset rheumatoid arthritis treated with four different
treatment strategies: a post hoc analysis from the BeSt trial. Ann Rheum
Dis 2010, 69:1342–1345.
15. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM,
Koutedakis Y, Kitas GD: Association of physical inactivity with increased
cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc
Prev Rehabil 2009, 16:188–194.
16. Panoulas VF, Douglas KM, Smith JP, Taffé P, Stavropoulos-Kalinoglou A,
Toms TE, Elisaf MS, Nightingale P, Kitas GD: Polymorphisms of the
endothelin-1 gene associate with hypertension in patients with
rheumatoid arthritis. Endothelium 2008, 15:203–212.
17. Panoulas VF, Douglas KM, Smith JP, Metsios GS, Elisaf MS, Nightingale P,
Kitas GD: Galectin-2 (LGALS2) 3279C/T polymorphism may be
independently associated with diastolic blood pressure in patients with
rheumatoid arthritis. Clin Exp Hypertens 2009, 31:93–104.
18. Liao KP, Solomon DH: Traditional cardiovascular risk factors, inflammation
and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford)
2013, 52:45–52.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G,
Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L,
Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, ESH-ESC Task Force
on the Management of Arterial Hypertension: 2007 ESH-ESC practice
guidelines for the management of arterial hypertension:ESH-ESC task force on the management of arterial hypertension.
J Hypertens 2007, 25:1751–1762.
20. Sandoo A, Panoulas VF, Toms TE, Smith JP, Stavropoulos-Kalinoglou A,
Metsios GS, Gasparyan AY, Carroll D, Veldhuijzen van Zanten JJ, Kitas GD:
Anti-TNFα therapy may lead to blood pressure reductions through
improved endothelium-dependent microvascular function in patients
with rheumatoid arthritis. J Hum Hypertens 2011, 25:699–702.
21. Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C,
Sfikakis PP: A pilot study of endothelial dysfunction and aortic stiffness
after interleukin-6 receptor inhibition in rheumatoid arthritis.
Atherosclerosis 2011, 219:734–736.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey
LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt
DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31:315–324.
23. Pitsavos C, Panagiotakos DB, Chrysohoou C, Stefanadis C: Epidemiology of
cardiovascular risk factors in Greece: aims, design and baseline
characteristics of the ATTICA study. BMC Public Health 2003, 3:32.
24. Stergiou GS, Tzamouranis D, Protogerou A, Nasothimiou E, Kapralos C:
Validation of the microlife watch BP office professional device for office
blood pressure measurement according to the international protocol.
Blood Press Monit 2008, 13:299–303.
25. Longo D, Dorigatti F, Palatini P: Masked hypertension in adults. Blood Press
Monit 2005, 10:307–310.
26. Stergiou GS, Giovas PP, Charilaos P, Gkinos CP, Patouras JD: Validation of
the microlife WatchBP home device for self home blood pressure
measurement according to the international protocol. Blood Press Monit
2007, 12:185–188.
27. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, Kario K, Lurbe E,
Manolis A, Mengden T, O’Brien E, Ohkubo T, Padfield P, Palatini P, Pickering TG,
Redon J, Revera M, Ruilope LM, Shennan A, Staessen JA, Tisler A, Waeber B,
Zanchetti A, Mancia G, ESH Working Group on Blood Pressure Monitoring:
European society of hypertension practice guidelines for home blood
pressure monitoring. J Hum Hypertens 2010, 24:779–785.
28. O’Brien E, Mee F, Atkins N, O’Malley K: Accuracy of the SpaceLabs 90207
determined by the British hypertension society protocol. J Hypertens
1991, 9:S25–S31.
29. Panagiotakos D, Pitsavos C, Arvaniti F, Stefanadis C: Adherence to the
Mediterranean food pattern predicts the prevalence of hypertension,
hypercholesterolemia, diabetes and obesity, among healthy adults; the
accuracy of the MedDietScore. Prev Med 2007, 44:335–340.
30. Kollias A, Xilomenos A, Protogerou A, Dimakakos E, Stergiou GS: Automated
determination of the ankle-brachial index using an oscillometric blood
pressure monitor: validation vs. Doppler measurement and
cardiovascular risk factor profile. Hypertens Res 2011, 34:825–830.
31. Stergiou GS, Thomopoulou GC, Skeva II, Mountokalakis TD: Prevalence,
awareness, treatment and control of hypertension in Greece: the Didima
study. Am J Hypertens 1999, 12:959–965.
32. Sarafidis PA, Lasaridis A, Gousopoulos S, Zebekakis P, Nikolaidis P, Tziolas I,
Papoulidou F: Prevalence, awareness, treatment and control of hypertension
in employees of factories of Northern Greece: the Naoussa study. J Hum
Hypertens 2004, 18:623–629.
33. Psaltopoulou D, Orfanos P, Naska A, Lenas D, Trichopoulos D, Trichopoulou A:
Prevalence awareness, treatment and control of hypertension in a general
population sample of 26 913 adults in the Greek EPIC study. Int J Epidemiol
2004, 33:1345–1352.
34. Efstratopoulos A, Voyaki SM, Baltas AA, Vratsistas FA, Kirlas DEP, Kontoyannis JT,
Sakellariou JG, Triantaphyllou GB, Alokrios GA, Lianas DN, Vasilakis EA, Fotiadis KN,
Kastritsea EE, Hypertenshell Investigators: Prevalence, awareness, treatment and
control of hypertension in Hellas, Greece: the hypertension study in general
practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens 2006,
19:53–60.
35. Panagiotakos DB, Pitsavos CH, Chrysohoou C, Skoumas J, Papadimitriou L,
Stefanadis C, Toutouzas PK: Status and management of hypertension in
Greece: role of the adoption of a Mediterranean diet: the Attica study.
J Hypertens 2003, 21:1483–1489.
36. Lee JS, Hayashi K, Mishra G, Yasui T, Kubota T, Mizunuma H: Independent
association between age at natural menopause and hypercholesterolemia,
hypertension, and diabetes mellitus: Japan nurses’ health study. J Atheroscler
Thromb 2013, 20:161–169.
Protogerou et al. Arthritis Research & Therapy 2013, 15:R142 Page 11 of 11
http://arthritis-research.com/content/15/5/R14237. Pikwer M, Bergström U, Nilsson JÅ, Jacobsson L, Turesson C: Early menopause
is an independent predictor of rheumatoid arthritis. Ann Rheum Dis 2012,
71:378–381.
38. Rozman B, Praprotnik S, Logar D, Tomsic M, Hojnik M, Kos-Golja M, Accetto R,
Dolenc P: Leflunomide and hypertension. Ann Rheum Dis 2002, 61:567–569.
39. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS,
Nightingale P, Kita MD, Elisaf MS, Kitas GD: Long-term exposure to
medium-dose glucocorticoid therapy associates with hypertension in
patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:72–75.
40. Protogerou AD, Zampeli E, Sfikakis PP: Low-dose prednisone inclusion in a
methotrexate-based, tight control strategy for early rheumatoid arthritis.
Ann Intern Med 2012, 157:299–300.
41. Sarafidis PA: Epidemiology of resistant hypertension. J Clin Hypertens
(Greenwich) 2011, 13:523–528.
42. Erdine S, Redon J, Böhm M, Ferri C, Kolloch R, Kreutz R, Laurent S, Persu A,
Schmieder RE, on behalf of the SHARE Steering Committee: Are physicians
underestimating the challenges of hypertension management? Results
from the Supporting Hypertension Awareness and Research Europe-
wide (SHARE) survey. Eur J Prev Cardiol 2013, 20:786–792.
43. Aytekin S, Guneri S, Cam N, Aydinlar A, Kozdag G, Ozerkan F, Yigit Z, Birdane A:
An observational study to evaluate factors responsible and actions taken
for hypertensive patients who are not at blood pressure goal: i-target Goal
Study. Hypertens Res 2012, 35:624–632.
44. Protogerou A, Blacher J, Stergiou GS, Achimastos A, Safar ME: Blood
pressure response under chronic antihypertensive drug therapy: the role
of aortic stiffness in the REASON (Preterax in regression of arterial
stiffness in a controlled double-blind) study. J Am Coll Cardiol 2009,
53:445–451.
45. Gorostidi M, de la Sierra A, González-Albarrán O, Segura J, de la Cruz JJ,
Vinyoles E, Llisterri JL, Aranda P, Ruilope LM, Banegas JR, Spanish Society of
Hypertension ABPM Registry Investigators: Abnormalities in ambulatory
blood pressure monitoring in hypertensive patients with diabetes.
Hypertens Res 2011, 34:1185–1189.
46. Panoulas VF, Toms TE, Metsios GS, Stavropoulos-Kalinoglou A, Kosovitsas A,
Milionis HJ, Douglas KM, John H, Kitas GD: Target organ damage in
patients with rheumatoid arthritis: the role of blood pressure and heart
rate. Atherosclerosis 2010, 209:255–260.
47. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK,
McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A,
Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N,
Nurmohamed MT: EULAR evidence-based recommendations for
cardiovascular risk management in patients with rheumatoid arthritis and
other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325–331.
doi:10.1186/ar4324
Cite this article as: Protogerou et al.: Arterial hypertension assessed
“out-of-office” in a contemporary cohort of rheumatoid arthritis patients
free of cardiovascular disease is characterized by high prevalence, low
awareness, poor control and increased vascular damage-associated
“white coat” phenomenon. Arthritis Research & Therapy 2013 15:R142.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
